1. Active matrix metalloproteinase-8 and interleukin-6 detect periodontal degeneration caused by radiotherapy of head and neck cancer: A pilot study
- Author
-
Keskin, Mutlu, Lahteenmaki, Hanna, Rathnayake, Nilminie, Raisanen, Ismo T., Tervahartiala, Taina, Parnanen, Pirjo, Sorsa, Timo, and Keskin, Mutlu
- Subjects
Il-6 ,Point Of Care Technology ,Radiotherapy ,Periodontitis ,aMMP-8 ,Head And Neck Cancer - Abstract
Raisanen, Ismo/0000-0001-5821-5299; Hagstrom, Jaana/0000-0001-6079-7881; Heikkila, Pia/0000-0002-5925-1993; Gursoy, Ulvi Kahraman/0000-0002-1225-5751 WOS:000605385500001 PubMed: 33406924 Background: This cohort study investigated the role of the active matrix metalloproteinase-8 (aMMP-8) and interleukin-6 (IL-6) as oral fluid biomarkers for monitoring the periodontal degeneration occurring in head and neck cancer (HNC) patients treated by radiotherapy. Research design and methods: Eleven patients, aged 28-74, diagnosed with HNC were included in the study. Complete periodontal and oral examinations were performed pre-radiotherapy and 1 month after radiotherapy. Mouthrinse samples (pre-radiotherapy, after 6 weeks of radiotherapy and 1 month after radiotherapy) were assayed by aMMP-8 point-of-care-kit (PerioSafe (R)/ORALyzer (R)) for aMMP-8 and ELISA for IL-6. Results: HNC radiotherapy had a deteriorating impact on the periodontium and a significant impact on periodontal biomarkers aMMP-8 and IL-6 and increased their levels in mouthrinse. Clinical-attachment-loss (CAL) (site of greatest loss: mean = 1.7 mm, range = 1-3 mm) corresponding to rapid progression of periodontitis. There was a positive repeated measures correlation (rmcorr = 0.667) between the aMMP-8 and IL-6 levels. Conclusions: Elevated aMMP-8 levels were observed 1 month after radiotherapy among some HNC patients suggesting a prolonged increased susceptibility to further periodontal tissue destruction. Currently available aMMP-8 point-of-care testing could be useful to monitor and assess quantitatively online and real-time the risk of deterioration of periodontal health during HNC radiotherapy. Helsinki University Hospital, Helsinki, Finland [TYH2016251, TYH2017251, TYH2018229, TYH2019319, Y1014SL017, Y1014SL018, Y1014SULE1]; Karolinska Institute, Stockholm, SwedenKarolinska Institutet This research was funded by the Helsinki University Hospital, Helsinki, Finland (grant numbers: TYH2016251, TYH2017251, TYH2018229, TYH2019319, Y1014SL017, Y1014SL018, Y1014SULE1), and the Karolinska Institute, Stockholm, Sweden. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
- Published
- 2020